310.ai

310.ai is a generative AI company specializing in molecular programming and programmable biology. Founded in 2022 by experts from Meta and Amgen, the company develops foundation models that translate biological language into functional protein sequences. Their flagship platform, Molecule Programming (MP), enables text-to-protein generation, allowing researchers to design de novo proteins, enzymes, and peptides from functional descriptions. By leveraging high-performance computing through partnerships with AMD and NVIDIA, 310.ai accelerates the drug discovery process from years to days. The company has demonstrated success in designing molecules for indications such as diabetes, weight loss, and heart disease, with high laboratory expression rates.